Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08MNO
|
||||
| Former ID |
DIB019036
|
||||
| Drug Name |
butaprost (free acid form)
|
||||
| Synonyms |
butaprost acid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [539192] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C23H38O5
|
||||
| InChI |
InChI=1S/C23H38O5/c1-2-13-23(14-8-15-23)21(26)11-7-10-18-17(19(24)16-20(18)25)9-5-3-4-6-12-22(27)28/h7,10,17-18,20-21,25-26H,2-6,8-9,11-16H2,1H3,(H,27,28)/b10-7+/t17-,18-,20-,21+/m1/s1
|
||||
| InChIKey |
PAYNQYXOKJDXAV-ZHIWTBQHSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Prostacyclin receptor | Target Info | Agonist | [525673] | |
| Prostaglandin E2receptor, EP2 subtype | Target Info | Agonist | [525571] | ||
| Prostaglandin E2 receptor EP3 subtype | Target Info | Agonist | [525673] | ||
| Thromboxane A2 receptor | Target Info | Agonist | [525673] | ||
| Prostaglandin E2 receptor, EP4 subtype | Target Info | Agonist | [534595] | ||
| Prostaglandin D2 receptor | Target Info | Agonist | [525673] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Vascular smooth muscle contraction | |||||
| Platelet activationhsa04024:cAMP signaling pathway | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| Renin secretion | |||||
| Pathways in cancerhsa04020:Calcium signaling pathway | |||||
| cAMP signaling pathway | |||||
| Regulation of lipolysis in adipocytes | |||||
| Platelet activationhsa04080:Neuroactive ligand-receptor interaction | |||||
| Pathways in cancerhsa04080:Neuroactive ligand-receptor interaction | |||||
| Pathway Interaction Database | Thromboxane A2 receptor signalingtxa2pathway:Thromboxane A2 receptor signaling | ||||
| Reactome | Prostanoid ligand receptors | ||||
| G alpha (s) signalling eventsR-HSA-391908:Prostanoid ligand receptors | |||||
| G alpha (i) signalling eventsR-HSA-391908:Prostanoid ligand receptors | |||||
| G alpha (q) signalling events | |||||
| G alpha (12/13) signalling events | |||||
| Thromboxane signalling through TP receptorR-HSA-391908:Prostanoid ligand receptors | |||||
| G alpha (s) signalling events | |||||
| WikiPathways | Prostaglandin Synthesis and Regulation | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Small Ligand GPCRs | |||||
| Endothelin Pathways | |||||
| Platelet homeostasis | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP98:Prostaglandin Synthesis and Regulation | |||||
| Ovarian Infertility Genes | |||||
| GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Signal amplification | |||||
| Vitamin D Receptor Pathway | |||||
| GPCR downstream signaling | |||||
| References | |||||
| Ref 525571 | Importance of the extracellular domain for prostaglandin EP(2) receptor function. Mol Pharmacol. 1999 Sep;56(3):545-51. | ||||
| Ref 525673 | The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. | ||||
| Ref 534595 | Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.